NEW YORK (Reuters Health) – Intensive control of blood pressure does have a clinically significant positive or negative impact on depression or patient-reported health-related quality of life, according…
NEW YORK (Reuters Health) – In patients with type 2 diabetes, intensive control of blood sugar reduces the risk of microalbuminuria and macroalbuminuria, but its impact on hard…
NEW YORK (Reuters Health) – Metformin appears to lower the risk of developing liver cancer in patients with type 2 diabetes, according to the results of a meta-analysis…
NEW YORK (Reuters Health) – Sleeve gastrectomy leads to significant improvement or resolution of type 2 diabetes in morbidly obese patients, and is much more effective than intensive…
NEW YORK (Reuters Health) – Long-term improvement in glycemic control seen with real-time continuous glucose monitoring (CGM) is similar whether used in a patient self-management protocol or in…
NEW YORK (Reuters Health) – Cigarette smoking enhanced the effects of clopidogrel in a study of diabetics with coronary artery disease. Accordingly, smokers were less likely to experience…
NEW YORK (Reuters Health) – The investigational GLP-1 receptor antagonist lixisenatide significantly reduces postprandial glucose excursions and HbA1c in patients with type 2 diabetes who have not been…
NEW YORK (Reuters Health) – In patients with type 2 diabetes whose glucose levels are inadequately controlled on high doses of insulin, the addition of dapagliflozin improves HbA1c…
NEW YORK (Reuters Health) – Iron-deficiency anemia can lead to high glycosylated hemoglobin (HbA1c) concentrations that do not reflect glycemic parameters, an Indian study has shown. “The use…
NEW YORK (Reuters Health) – In patients with type 2 diabetes, glycemic control is better and weight loss is sustained up to 84 weeks with exenatide once weekly…